Other · France · EU Transparency Register 01150446981-34
8
positions filed
in the 665 files tracked
7
legislative files
of 665 tracked
7
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1106 non-governmental organisations on this site, they rank #179 by legislative files engaged, a count of participation, not a measure of influence.
7
declared lobbying FTE
self-declared
€600K+
declared costs / yr (floor)
3
EP accreditations
as declared to the register
2011
in the register since
Declares membership of
European Chronic Disease Alliance (ECDA)
Alliance for Biomedical Research in Europe (BioMed Alliance)
World Heart Federation
European Alliance for Cardiovascular Health (EACH)
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
Register category
Non-governmental organisations
Head office
Sophia Antipolis Cedex, France
EU office
Brussels
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Work at European Society of Cardiology? so we know who speaks for it.
Their record over time
European Society of Cardiology filed 8 positions between 1 Feb 2021 and 28 Sept 2026, across 7 of the 665 legislative files tracked here, attaching a full position paper 7 times.
Statement of the European Society of Cardiology in response to the European Commission’s proposal for a regulation of the European Parliament and of the Council establishing Horizon Europe, the Framework Programme for Research and Innovation, for the period 2028-2034 The European Society of Cardiology (ESC), a volunteer-led, not-for-profit medical society uniting over 100,000 clinicians, scientists, nurses, and…
Opening of the attached position paper · the full paper is on the Commission’s record (source link above)
The European Society of Cardiology (ESC) welcomes the evaluation and revision of the EU pharmaceutical legislation. As leading professional organisation in cardiovascular healthcare, we are dedicated to providing effective, safe and innovative cardiovascular therapy to our patients. We share the impression that the COVID-19 pandemic has revealed both strengths and weaknesses of the EU pharmaceutical legislation.
The European Society of Cardiology welcomes the European Commission’s initiative to create a European Health Data Space for better healthcare, research, and policymaking. The COVID pandemic has clearly shown the weakness to overcome healthcare challenges and lack of collaboration between Member States and their data exchange due to national legal constraints.
The European Society of Cardiology (ESC) welcomes the European Commissions work on early detection and screening under the EU Safe Hearts Plan, including the forthcoming Council Recommendation on health checks for cardiovascular diseases.
Statement of the European Society of Cardiology in response to the European Commission’s call for evidence on the Quality Jobs Act Introduction and rationale The European Society of Cardiology (ESC), a volunteer-led, not-for-profit medical society uniting over 100,000 clinicians, scientists, nurses, and allied professionals working across all fields of cardiovascular medicine and surgery, applauds the European…
Opening of the attached position paper · the full paper is on the Commission’s record (source link above)
The European Society of Cardiology (ESC) fully supports the initiative to reinforce the mandate of the ECDC and calls for the mandate to be extended beyond communicable diseases. The COVID-19 pandemic has indeed clearly demonstrated that communicable and non-communicable diseases are closely intertwined and that the collateral damage to patients with communicable diseases needs to be evaluated to assess the…
The European Society of Cardiology (ESC) fully supports the initiative to reinforce the mandate of the ECDC and calls for the mandate to be extended beyond communicable diseases. The COVID-19 pandemic has indeed clearly demonstrated that communicable and non-communicable diseases are closely intertwined and that the collateral damage to patients with communicable diseases needs to be evaluated to assess the…
The European Society of Cardiology (ESC) supports the initiative to reinforce the mandate of European Medicines Agency (EMA) to enable the Agency to lead a more effective response to health crises, both caused by communicable and non-communicable diseases. The ESC and National Cardiac Societies across Europe share the goal of reducing the burden of cardiovascular disease (CVD).
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put European Society of Cardiology next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Everything on this page comes from European Society of Cardiology’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.
